Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics.

Ischemic stroke triggers a complex and highly interconnected cascade of cellular and molecular events. Early events induced following ischemic injury, including excitotoxicity, calcium overload and oxidative stress, rapidly result in cell death in the infarct core. Later events, such as neuroinflammation and apoptosis, are relevant to the death of the ischemic penumbra. Drugs that limit delayed-injury events have a wide therapeutic window for protection; however, the damaging events of the ischemic cascade will eventually prevail if reperfusion is not achieved within minutes after ischemia. The combination of thrombolytics with protective drugs may provide a promising therapy in the management of stroke. Targeting all components of the neurovascular unit, rather than just the neuron, should be a priority in stroke research, and agents that block multiple events of the injury cascade are more likely to provide cerebroprotection. Understanding when the brain begins the transition from injury to repair could have important implications for stroke therapy. Several ischemic mediators have dual roles, with detrimental acute effects, but beneficial effects in the repair phase; therefore, extending experimental stroke investigations to an analysis of the long-term outcome is important. This review provides a critical evaluation of promising therapeutic strategies for ischemic stroke, and a translational perspective on how to improve success in the development of novel pharmaceuticals for cerebral ischemia.

[1]  Marc Fisher,et al.  Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations , 2009, Stroke.

[2]  Markus Schwaninger,et al.  Improving Outcome after Stroke: Overcoming the Translational Roadblock , 2008, Cerebrovascular Diseases.

[3]  O. Lindvall,et al.  Long-Term Neuroblast Migration Along Blood Vessels in an Area With Transient Angiogenesis and Increased Vascularization After Stroke , 2007, Stroke.

[4]  M. Pangalos,et al.  The development of stroke therapeutics: Promising mechanisms and translational challenges , 2009, Neuropharmacology.

[5]  G. Rosenberg,et al.  Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. , 1998, Stroke.

[6]  R. M. Adibhatla,et al.  Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. , 2006, Free radical biology & medicine.

[7]  S. Warach,et al.  A randomized dose-response trial of citicoline in acute ischemic stroke patients , 1997, Neurology.

[8]  E. Lo,et al.  Multiphasic roles for matrix metalloproteinases after stroke. , 2008, Current opinion in pharmacology.

[9]  G. Rosenberg,et al.  Closure of the Blood-Brain Barrier by Matrix Metalloproteinase Inhibition Reduces rtPA-Mediated Mortality in Cerebral Ischemia With Delayed Reperfusion , 2003, Stroke.

[10]  A. Shuaib,et al.  The Past and Future of Neuroprotection in Cerebral Ischaemic Stroke , 2007, European Neurology.

[11]  L. Wechsler,et al.  A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients , 2001, Neurology.

[12]  R. Busto,et al.  Albumin Therapy Augments the Effect of Thrombolysis on Local Vascular Dynamics in a Rat Model of Arteriolar Thrombosis: A Two-Photon Laser-Scanning Microscopy Study , 2008, Stroke.

[13]  J. Koziol,et al.  Matrix Metalloproteinases Increase Very Early during Experimental Focal Cerebral Ischemia , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  Steven C. Cramer Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery , 2008, Annals of neurology.

[15]  E. Lo,et al.  MMP-9–Positive Neutrophil Infiltration Is Associated to Blood–Brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation After Human Ischemic Stroke , 2008, Stroke.

[16]  Olivier Rouaud,et al.  Epidemiology of stroke in Europe: Geographic and environmental differences , 2007, Journal of the Neurological Sciences.

[17]  J. Arenillas,et al.  Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke , 2003, Circulation.

[18]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Neuroblast Cell Migration from the Subventricular Zone after Stroke , 2006, The Journal of Neuroscience.

[19]  Jan van Gijn,et al.  Acute Ischemic Stroke , 2007 .

[20]  G. Rosenberg,et al.  Multiple roles for MMPs and TIMPs in cerebral ischemia , 2005, Glia.

[21]  W. Clark,et al.  A randomized efficacy trial of citicoline in patients with acute ischemic stroke. , 1999, Stroke.

[22]  A. Dávalos,et al.  Neuroprotection in Cerebral Infarction: The Opportunity of New Studies , 2007, Cerebrovascular Diseases.

[23]  O. Hurtado,et al.  Synthesis of Lipoxin A4 by 5-Lipoxygenase Mediates PPARγ-Dependent, Neuroprotective Effects of Rosiglitazone in Experimental Stroke , 2009, The Journal of Neuroscience.

[24]  M. Chopp,et al.  Matrix Metalloproteinase 2 (MMP2) and MMP9 Secreted by Erythropoietin-Activated Endothelial Cells Promote Neural Progenitor Cell Migration , 2006, The Journal of Neuroscience.

[25]  E. Lo,et al.  Increased Brain Expression of Matrix Metalloproteinase-9 After Ischemic and Hemorrhagic Human Stroke , 2006, Stroke.

[26]  Yi Li,et al.  Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke , 2003, Annals of neurology.

[27]  Steven Warach,et al.  Early blood–brain barrier disruption in human focal brain ischemia , 2004, Annals of neurology.

[28]  E. Candelario-Jalil,et al.  Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia , 2009, Neuroscience.

[29]  J. Mitchell,et al.  COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs , 2006, Nature Reviews Drug Discovery.

[30]  J. Wellmann,et al.  Meta-Analysis of the Efficacy of Granulocyte-Colony Stimulating Factor in Animal Models of Focal Cerebral Ischemia , 2008, Stroke.

[31]  Steven C Cramer,et al.  Repairing the human brain after stroke. II. Restorative therapies , 2008, Annals of neurology.

[32]  M. T. Medina,et al.  Stroke epidemiology, prevention, and management strategies at a regional level: Latin America and the Caribbean , 2007, The Lancet Neurology.

[33]  B. Fiebich,et al.  Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat , 2004, Brain Research.

[34]  B. Fiebich,et al.  Cyclooxygenase inhibition in ischemic brain injury. , 2008, Current pharmaceutical design.

[35]  F. Barone,et al.  Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  V. Feigin,et al.  Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century , 2003, The Lancet Neurology.

[37]  S. Taheri,et al.  Early Beneficial Effect of Matrix Metalloproteinase Inhibition on Blood—Brain Barrier Permeability as Measured by Magnetic Resonance Imaging Countered by Impaired Long-Term Recovery after Stroke in Rat Brain , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  U. Dirnagl,et al.  Inflammation in stroke: the good, the bad, and the unknown. , 2004, Ernst Schering Research Foundation workshop.

[39]  B. Fiebich,et al.  Post‐ischaemic treatment with the cyclooxygenase‐2 inhibitor nimesulide reduces blood–brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats , 2007, Journal of neurochemistry.

[40]  N. Patel,et al.  Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury , 2008, Therapeutic advances in cardiovascular disease.

[41]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[42]  T. Herdegen,et al.  PPAR-γ: therapeutic target for ischemic stroke , 2007 .

[43]  Hans-Christoph Diener,et al.  NXY-059 for the treatment of acute ischemic stroke. , 2007, The New England journal of medicine.

[44]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats , 2002, Stroke.

[45]  M. Boaz,et al.  MINOCYCLINE TREATMENT IN ACUTE STROKE : AN OPEN-LABEL, EVALUATOR-BLINDED STUDY. Authors' reply , 2008 .

[46]  Yasuto Itoyama,et al.  Reduction of Ischemic Damage by Application of Vascular Endothelial Growth Factor in Rat Brain after Transient Ischemia , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  M. Chopp,et al.  Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. , 2002, Trends in cardiovascular medicine.

[48]  W. Ding,et al.  Electron Paramagnetic Resonance-Guided Normobaric Hyperoxia Treatment Protects the Brain by Maintaining Penumbral Oxygenation in a Rat Model of Transient Focal Cerebral Ischemia , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[49]  R. Sood,et al.  Normobaric hyperoxia inhibits NADPH oxidase‐mediated matrix metalloproteinase‐9 induction in cerebral microvessels in experimental stroke , 2008, Journal of neurochemistry.

[50]  Tamara Roitbak,et al.  Neural Stem/Progenitor Cells Promote Endothelial Cell Morphogenesis and Protect Endothelial Cells against Ischemia via HIF-1α-Regulated VEGF Signaling , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[51]  Jeffrey F. Thompson,et al.  Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[52]  M. Ross,et al.  Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Singhal A review of oxygen therapy in ischemic stroke , 2007, Neurological research.

[54]  Myron D. Ginsberg,et al.  Neuroprotection for ischemic stroke: Past, present and future , 2008, Neuropharmacology.

[55]  Henrik Ahlenius,et al.  Persistent Production of Neurons from Adult Brain Stem Cells During Recovery after Stroke , 2006, Stem cells.

[56]  Rona G. Giffard,et al.  Microglia Potentiate Damage to Blood–Brain Barrier Constituents: Improvement by Minocycline In Vivo and In Vitro , 2006, Stroke.

[57]  Gang Wang,et al.  Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity , 2006, Nature Medicine.

[58]  E. Ling,et al.  Blood brain barrier in hypoxic-ischemic conditions. , 2008, Current neurovascular research.

[59]  Ping Zhou,et al.  The Neuroprotective Effect of Prostaglandin E2 EP1 Receptor Inhibition has a Wide Therapeutic Window, is Sustained in Time and is not Sexually Dimorphic , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[60]  M. Fisher Stroke and TIA: epidemiology, risk factors, and the need for early intervention. , 2008, The American journal of managed care.

[61]  E. Lo,et al.  Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9 Expression During Reperfusion Injury: Mechanical Versus Embolic Focal Ischemia in Spontaneously Hypertensive Rats , 2002, Stroke.

[62]  T. Wieloch,et al.  Mechanisms of neural plasticity following brain injury , 2006, Current Opinion in Neurobiology.

[63]  Barry Halliwell,et al.  Oxidative stress and neurodegeneration: where are we now? , 2006, Journal of neurochemistry.

[64]  W. Schäbitz,et al.  Multifunctional actions of approved and candidate stroke drugs , 2011, Neurotherapeutics.

[65]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[66]  E. Díez-Tejedor,et al.  Lipid-Lowering Drugs in Ischemic Stroke Prevention and Their Influence on Acute Stroke Outcome , 2009, Cerebrovascular Diseases.

[67]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[68]  A. Shah,et al.  Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. , 2005, American journal of physiology. Heart and circulatory physiology.

[69]  K. Jin,et al.  VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. , 2003, The Journal of clinical investigation.

[70]  S. Warach,et al.  Thrombolytic Toxicity: Blood Brain Barrier Disruption in Human Ischemic Stroke , 2008, Cerebrovascular Diseases.

[71]  K. Rhodes,et al.  Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke , 2008, Stroke.

[72]  J. Phillis,et al.  Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders , 2006, Brain Research Reviews.

[73]  David A Boas,et al.  Normobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia. , 2007, Brain : a journal of neurology.

[74]  B. Rosen,et al.  Role of matrix metalloproteinases in delayed cortical responses after stroke , 2006, Nature Medicine.

[75]  S. L. Mehta,et al.  Molecular targets in cerebral ischemia for developing novel therapeutics , 2007, Brain Research Reviews.

[76]  H. Okano,et al.  Implication of cyclooxygenase‐2 on enhanced proliferation of neural progenitor cells in the adult mouse hippocampus after ischemia , 2003, Journal of neuroscience research.

[77]  Nirds,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group , 1995 .

[78]  E. Lo,et al.  A new penumbra: transitioning from injury into repair after stroke , 2008, Nature Medicine.